ClinicalTrials.gg
TerminatedNCT06444451Updated Aug 10, 2026

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

A Phase 2 interventional study of Amlitelimab and Placebo in Alopecia Areata, sponsored by Sanofi. Terminated at 74 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision; the decision is not related to any safety concern

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
15th of 84
166 · median 46
Started
2024
with 6 others
Phase 2
42 of 98
8 open now
Registered
78th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 15th largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2024, is one of 42 in phase 2, and was the 78th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in participants aged 18 years and older with severe alopecia areata (AA). At the end of the double-blind treatment period, all participants will have the option to enter the open-label extension (OLE) period.

The study duration will be up to 160 weeks for participants entering the OLE period including a 2-to-4-week screening, a 36-week randomized double-blind period, an optional OLE period (104 weeks) and a 16-week safety follow-up. The open-label extension period is optional and open to all participants who have completed the double-blind treatment period.

The total number of visits will be up to 38 visits (or 12 visits for those not entering the OLE study).

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definitive diagnosis of AA of more than 6 months.
  • Diagnosis of severe AA, as determined by all of the following:

    1. Hair loss affecting ≥50% of the scalp, as measured by Severity of Alopecia Tool (SALT) at both screening and baseline visits.
    2. Current episode of severe hair loss of less than 8 years. Participants with a history of AA of more than 8 years who have observed episodes of terminal hair regrowth over their scalp ("moving patches" spontaneously or following treatment) in the past 8 years can be included.
    3. Stable disease: no evidence of terminal hair regrowth within 6 months (less than 10% improvement over the past 6 months). (guidance: if participant reports to have quite a bit more hair than 6 months prior, then patient cannot be included).
  • Willingness in maintaining a consistent hair style and hair care, including hair products, and to refrain from weaves, extensions, adhesive wigs, other than banded perimeter devices, refrain from shaving of scalp hair for 2 weeks prior to each study visit from baseline to the end of study.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participants that are currently experiencing other forms of alopecia, including but not limited to: androgenetic alopecia, trichotillomania, telogen effluvium, traction alopecia, scarring alopecia.
  • Participants currently with any local or systemic active medical conditions, which in the opinion of the Investigator would interfere with evaluations of the IMP effect on AA due to scalp inflammation, including but not limited to seborrheic dermatitis requiring topical treatment to the scalp, lupus erythematosus, lichen planus, psoriasis, secondary syphilis, tinea capitis, thyroiditis, systemic sclerosis, hair transplants, micropigmentation/tattoo of the scalp.
  • Received the specified treatment regimens within the timeframe outlined in the protocol.
  • Prior use of any oral JAKi or the topical JAKi ruxolitinib for more than 24 months, regardless if is respected.
  • Participants with shaved heads must not enter the study until hair has grown back and SALT score can be reliably administered.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose group 1

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Experimental
    Amlitelimab dose group 2

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Subcutaneous injection as per protocol

    Drug: Placebo

Interventions

  • Pharmaceutical form: Injection solution Route of administration: SC injection

    Also known as: SAR445229

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: SC injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in Severity of Alopecia Tool (SALT) score at Week 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Baseline to Week 36

Secondary outcomes

  1. Change from the baseline in SALT score at Week 24 (key secondary)

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Baseline to Week 24

  2. Proportion of participants achieving a SALT score ≤20 at Weeks 24 and 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Week 24 and 36

  3. Time to SALT score ≤20

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Up to Week 36

  4. Proportion of participants achieving a SALT score ≤10 at Weeks 24 and 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Week 24 and 36

  5. Time to SALT score ≤10

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss).

    Time frame: Up to Week 36

  6. Proportion of participants achieving a SALT50 at Weeks 24 and 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). SALT50 is 50% reduction from baseline in SALT score.

    Time frame: Week 24 and 36

  7. Proportion of participants achieving a SALT75 at Weeks 24 and 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). SALT75 is 75% reduction from baseline in SALT score.

    Time frame: Week 24 and36

  8. Proportion of participants achieving a SALT90 at Weeks 24 and 36

    SALT is a quantitative Investigator assessment of AA severity scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). SALT90 is 90% reduction from baseline in SALT score.

    Time frame: Week 24 and 36

  9. Proportion of participants achieving ClinRO Measure for eyebrow (EB) Hair Loss 0 or 1 with ≥2-point improvement from baseline at Weeks 24 and 36 (among participants with ClinRO Measure for EB Hair Loss ≥2 at Baseline)

    ClinRO Measure for EB Hair Loss is a single item, clinician-reported numeric rating scale (NRS) measuring eyebrow hair loss. Scores range from 0 = normal appearance/no eyebrow hair loss to 3 = severe appearance/severe eyebrow hair loss

    Time frame: Week 24 and 36

  10. Proportion of participants achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 with ≥2-point improvement from baseline (among participants with ClinRO Measure for EL Hair Loss ≥2 at Baseline)

    ClinRO Measure for EL Hair Loss is a single item, clinician-reported numeric rating scale (NRS) measuring eyelash hair loss. Scores range from 0 = normal appearance/no eyelash hair loss to 3 = severe appearance/severe eyelash hair loss.

    Time frame: Week 24 and 36

  11. Proportion of participants achieving a PGI-C response defined as a score of "moderately improved" or "greatly improved" at Weeks 24 and 36

    The Patient Global Impression of Change (PGI-C) is a questionnaire that asks participants to provide the overall self-assessment of change in their AA overall on a 5-point scale. The PGI-C will be scored from 1 = Much better to 5 = Much worse.

    Time frame: Week 24 and 36

  12. Proportion of participants achieving a PGI-S response defined as a score of "mild" or "none" at Weeks 24 and 36

    The Patient Global Impression of Severity (PGI-S) is a single item 5-point scale (1 = no symptoms to 5 = very severe symptoms) which asks a participant to assess current severity of AA symptoms.

    Time frame: Week 24 and 36

  13. Mean changes from baseline in SKINDEX-16AA at Weeks 24 and 36

    Skindex-16 for alopecia areata (SKINDEX-16AA) is a tool used to assess the health-related quality of life in participants with skin disorders. The score ranges from 0 to 100, with higher scores indicating a greater burden of AA on the patient.

    Time frame: Baseline to Week 24 and 36

  14. Proportion of participants with PRO Scalp Hair Assessment score of 0 to 1 with ≥2-point improvement from baseline (among participants with PRO Scalp Hair Assessment score ≥3 at Baseline)

    Scalp Hair Assessment patient reported outcome (PRO) is a single item, patient-reported NRS using a 5-point response scale and ranging from 0 to 4, with 0 = no missing hair (0% scalp hair missing) and 4 = nearly all or all missing hair (95- 100% scalp hair missing).

    Time frame: Week 24 and 36

  15. Proportion of participants achieving grade 0 or 1 with ≥2-point improvement from baseline PRO Measure for EB Hair Loss (among participants with PRO Measure for EB Hair Loss ≥2 at Baseline)

    PRO Measure for Eyebrow Hair Loss™ is a single item, patient-reported NRS measuring eyebrow hair loss, ranging from 0 to 3, with 0 = full coverage/no eyebrow hair loss and 3 = barely any/no notable eyebrow hair.

    Time frame: Week 24 and 36

  16. Proportion of participants achieving grade 0 or 1 with ≥2-point improvement from baseline PRO Measure for EL Hair Loss at Weeks 24 and 36 (among participants with PRO Measure for EL Hair Loss ≥2 at Baseline)

    PRO Measure foe Eyelash Hair Loss™ is a single item, patient-reported NRS measuring eyelash hair loss, ranging from 0 to 3, with 0 = full coverage/no eyelash hair loss and 3 = barely any/no notable eyelash hair.

    Time frame: Week 24 and 36

  17. Proportion of participants who experienced treatment-emergent adverse events (TEAEs), experienced treatment-emergent serious adverse event (TESAEs) and/or Treatment-Emergent adverse event of special interest (AESIs)

    Time frame: Up to week 156

  18. Serum amlitelimab concentrations measured at prespecified timepoints

    Time frame: Up to Week 156

  19. Incidence of ADAs of amlitelimab at prespecified timepoints

    Time frame: Up to Week 156

07

Study locations

74 sites
  • Total Skin and Beauty Dermatology Center- Site Number : 8400018
    Birmingham, Alabama 35205, United States
  • First OC Dermatology- Site Number : 8400014
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research- Site Number : 8400008
    Fremont, California 94538, United States
  • UC Irvine Healthcare - Gottschalk Medical Plaza- Site Number : 8400007
    Irvine, California 92697, United States
  • Dermatology Research Associates - Los Angeles- Site Number : 8400015
    Los Angeles, California 90045, United States
  • New Horizon Research Center- Site Number : 8400017
    Miami, Florida 33165, United States
  • Dawes Fretzin Clinical Research- Site Number : 8400010
    Indianapolis, Indiana 46256, United States
  • Michigan Center for Research Company- Site Number : 8400016
    Clarkston, Michigan 48346, United States
  • Joel Schlessinger, PC- Site Number : 8400021
    Omaha, Nebraska 68144, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400003
    New York, New York 10029, United States
  • DJL Clinical Research - Charlotte - Park Road- Site Number : 8400013
    Charlotte, North Carolina 28210, United States
  • Cleveland Clinic- Site Number : 8400028
    Cleveland, Ohio 44195, United States
  • Apex Clinical Research Center- Site Number : 8400027
    Mayfield Heights, Ohio 44124, United States
  • Vital Prospects Clinical Research Institute - Tulsa- Site Number : 8400004
    Tulsa, Oklahoma 74136, United States
  • Oregon Medical Research Center- Site Number : 8400002
    Portland, Oregon 97201, United States
  • Health Concepts- Site Number : 8400001
    Rapid City, South Dakota 57702, United States
  • Progressive Clinical Research - San Antonio- Site Number : 8400019
    San Antonio, Texas 78229, United States
  • Investigational Site Number : 0320002
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1055, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1061, Argentina
  • Investigational Site Number : 0360001
    Sydney, New South Wales 2010, Australia
  • Investigational Site Number : 0360003
    Melbourne, Victoria 3002, Australia
  • Investigational Site Number : 1000001
    Sofia, 1612, Bulgaria
  • Investigational Site Number : 1240005
    Calgary, Alberta T2J 7E1, Canada
  • Investigational Site Number : 1240007
    Calgary, Alberta T2W 4X9, Canada
  • Investigational Site Number : 1240001
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigational Site Number : 1240003
    Hamilton, Ontario L8L 3C3, Canada
  • Investigational Site Number : 1240006
    Markham, Ontario L3P 1X2, Canada
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number : 1560022
    Chengdu, 610041, China
  • Investigational Site Number : 1560006
    Hangzhou, 310009, China
  • Investigational Site Number : 1560001
    Shanghai, 200040, China
  • Investigational Site Number : 2032104
    Ostrava, 702 00, Czechia
  • Investigational Site Number : 2030011
    Prague, 150 00, Czechia
  • Investigational Site Number : 2030012
    Prague, 158 00, Czechia
  • Investigational Site Number : 2500001
    Brest, 29200, France
  • Investigational Site Number : 2500002
    Nice, 06202, France
  • Investigational Site Number : 2500003
    Paris, 75010, France
  • Investigational Site Number : 2500004
    Rouen, 76031, France
  • Investigational Site Number : 2760006
    Augsburg, 86150, Germany
  • Investigational Site Number : 2760008
    Berlin, 10117, Germany
  • Investigational Site Number : 2760007
    Berlin, 10629, Germany
  • Investigational Site Number : 2760001
    Hamburg, 20095, Germany
  • Investigational Site Number : 2760003
    Münster, 48149, Germany
  • Investigational Site Number : 2760004
    Osnabrück, 49074, Germany
  • Investigational Site Number : 3800004
    Milan, Milano 20132, Italy
  • Investigational Site Number : 3800003
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800002
    Rome, Roma 00168, Italy
  • Investigational Site Number : 3800001
    Bologna, 40138, Italy
  • Investigational Site Number : 3920003
    Ebina-shi, Kanagawa 243-0432, Japan
  • Investigational Site Number : 3920001
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number : 3920002
    Kamiamakusa, Kumamoto 861-3106, Japan
  • Investigational Site Number : 3920005
    Koto-ku, Tokyo 136-0075, Japan
  • Investigational Site Number : 3920004
    Fukuoka, 814-0171, Japan
  • Investigational Site Number : 3920006
    Tokyo, 160-0023, Japan
  • Investigational Site Number : 3920001
    Yokohama, 221-0825, Japan
  • Investigational Site Number : 5280004
    Rotterdam, 3015 CE, Netherlands
  • Investigational Site Number : 6420001
    Cluj-Napoca, 400006, Romania
  • Investigational Site Number : 7240005
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240010
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number : 7240007
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Investigational Site Number : 7240004
    Alicante, 03010, Spain
  • Investigational Site Number : 7240002
    Córdoba, 14004, Spain
  • Investigational Site Number : 7240006
    Madrid, 28031, Spain
  • Investigational Site Number : 7240008
    Madrid, 28040, Spain
  • Investigational Site Number : 8260003
    London, London, City of SW10 9NH, United Kingdom
  • Investigational Site Number : 8260004
    Salford, Manchester M6 8HD, United Kingdom
  • Investigational Site Number : 8260006
    Oxford, Oxfordshire OX3 7LE, United Kingdom
  • Investigational Site Number : 8260005
    Dundee, DD1 9SY, United Kingdom
  • Investigational Site Number : 8260007
    London, SE1 9RT, United Kingdom
  • Investigational Site Number : 8260001
    London, SE5 9RL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Sep 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 5, 2024
StartActual
Jun 6, 2024
Primary completionActual
Sep 24, 2025
CompletionActual
May 21, 2026
Results delay requested
Aug 6, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444451
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Jun 6, 2024
Primary completion
Sep 24, 2025
Completion
May 21, 2026
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion